Overlapping CNS inflammatory diseases: Differentiating features of NMO and MS

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 1, 2015, Pages 20-25

  Juryńczyk, Maciej ^a   Craner, Matthew ^a   Palace, Jacqueline ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLIAL FIBRILLARY ACIDIC PROTEIN; OLIGOCLONAL BAND; ANTIBODY; AQUAPORIN 4; BIOLOGICAL MARKER;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONVALESCENCE; DEMOGRAPHY; DISABILITY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; EOSINOPHIL COUNT; GEOGRAPHIC DISTRIBUTION; HUMAN; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NAUSEA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PHENOTYPE; PLEOCYTOSIS; TRANVERSE MYELITIS; TREATMENT PLANNING; WHITE MATTER LESION; BLOOD; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; NEUROMYELITIS OPTICA;

ANTIBODIES; AQUAPORIN 4; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

EID: 84919723267     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308984     Document Type: Article

References (82)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica. Lancet 2004;364:2106-12.
3. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-7.
4. Roemer SF, Parisi JE, Lennon VA, et al . Pattern-speci fic loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194-205.
5. Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133:349-61.
6. Kitley J, Evangelou N, Küker W, et al. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci 2014;339:3-5.
7. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-7.
8. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276-83.
9. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-27.
10. Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009;15:159-73.
11. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-71.
12. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834-49.
13. Mealy MA, Wingerchuk DM, Greenberg BM, et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012;69:1176-80.
14. Piccolo L, Kumar G, Nakashima I, et al. Multiple sclerosis in Japan appears to be a milder disease compared to the UK. Submitted.
15. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8.
16. Schultheiss T, Reichmann H, Ziemssen T. Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report. Mult Scler 2011;17:245-9.
17. Quek AML, McKeon A, Lennon VA, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol 2012;69:1039-43.
18. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
19. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013;80:2194-200.
20. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-204.
21. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-19.
22. Matiello M, Kim HJ, Kim W, et al. Familial neuromyelitis optica. Neurology 2010;75:310-15.
23. Asgari N, Nielsen C, Stenager E, et al. HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica. Mult Scler 2012;18:23-30.
24. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68:603-5.
25. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-200.
26. Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 2010;81:109-11.
27. Group ONS. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008;115:1079-82.e5.
28. Nakajima H, Hosokawa T, Sugino M, et al. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol 2010;10:45.
29. Merle H, Olindo S, Jeannin S, et al. Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis. Clin Ophthalmol 2013;7:1145-53.
30. Burman J, Raininko R, Fagius J. Bilateral and recurrent optic neuritis in multiple sclerosis. Acta Neurol Scand 2011;123:207-10.
31. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008;71:93-100.
32. Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012;32:216-20.
33. Tackley G, Kuker W, Palace J. Magnetic resonance imaging in neuromyelitis optica. Mult Scler 2014;20:1153-64.
34. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009;72:1077-82.
35. Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009;73:302-8.
36. De Seze J, Blanc F, Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol 2008;65:920-3.
37. Schneider E, Zimmermann H, Oberwahrenbrock T, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One 2013;8:e66151.
38. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
39. Krampla W, Aboul-Enein F, Jecel J, et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 2009;19:2535-43.
40. Pittock SJ, Weinshenker BG, Wijdicks EFM. Mechanical ventilation and tracheostomy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:1331-3.
41. Bot JCJ, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226-33.
42. Tartaglino LM, Friedman DP, Flanders AE, et al. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 1995;195:725-32.
43. Qiu W, Wu J-S, Zhang M-N, et al. Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database. J Neurol Neurosurg Psychiatry 2010;81:209-12.
44. Kitley JL, Leite MI, George JS, et al. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 2012;18:271-85.
45. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 2008;255:163-70.
46. Klawiter EC, Xu J, Naismith RT, et al. Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler 2012;18:1259-68.
47. Ciccarelli O, Thomas DL, De Vita E, et al. Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. Ann Neurol 2013;47:301-5.
48. Pessôa FMC, Lopes FCR, Costa JVA, et al. The cervical spinal cord in neuromyelitis optica patients: a comparative study with multiple sclerosis using diffusion tensor imaging. Eur J Radiol 2012;81:2697-701.
49. Devic E. Myelite subaigue compliquee de nevrite optique. Bull Med 1894;8:1033-4.
50. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-81.
51. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-82.
52. Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010;68:757-61.
53. Viegas S, Weir A, Esiri M, et al. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2009;80:679-82.
54. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-8.
55. Qiu W, Raven S, Wu J-S, et al. Hypothalamic lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry 2011;82:819-22.
56. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-6.
57. Matthews L, Marasco R, Jenkinson M, et al . Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013;80:1330-7.
58. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120(Pt 1):2059-69.
59. Asgari N, Lillevang ST, Skejoe HPB, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011;76:1589-95.
60. Sinnecker T, Dörr J, Pfueller CF, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 2012;79:708-14.
61. Calabrese M, Oh MS, Favaretto A, et al. No MRI evidence of cortical lesions in neuromyelitis optica. Neurology 2012;79:1671-6.
62. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14.
63. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:78-83.
64. Iyer A, Elsone L, Appleton R, et al. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 2014;6934:1-8.
65. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012;18:5-10.
66. Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 2012;78:1601-7.
67. Sylvester J, Purdie G, Slee M, et al. Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: a case report and literature review. J Neuroimmunol 2013;264:130-3.
68. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39:87-90.
69. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
70. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid fi ndings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306:82-90.
71. Ebers GC, Paty DW. CSF electrophoresis in one thousand patients. Can J Neurol Sci 1980;7:275-80.
72. McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 1990;113(Pt 5):1269-89.
73. Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208-16.
74. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011;108:3701-6.
75. Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009;256:2082-4.
76. Matsushita T, Tateishi T, Isobe N, et al. Characteristic cerebrospinal fluid cytokine/ chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013;8:e61835.
77. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010;75:1423-7.
78. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-45.
79. Jacob A, Kelly S, Ali R, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012;79:1065-9.
80. Palace J, Leite MI, Nairne A, et al. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67:1016-7.
81. Jury ńczyk M, Zaleski K, Selmaj K. Natalizumab and the development of extensive brain lesions in neuromyelitis optica. J Neurol 2013;260:1919-21.
82. Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler J 2012;18:113-15.